arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Zoetis Inc.

ZTS
$72.63 ▼ -4.60 (-5.96%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
68
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

Zoetis Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Debt to Equity which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $30.7B
Dividend Yield 0.73%
Revenue Growth 1.9%
Op. Margin
ROIC
FCF / Share $0.69
Trailing P/E 51.2x
Price / Book 9.4x
FCF Yield 1.0%
Debt / Equity 2.80
info Valuation on last close. End-of-day price, Aug 7, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.26B
↑ +1.9%
Net Income Profit after all expenses
$601.00M
↓ -4.8%
FCF / Share Free cash flow per share
$0.69
↓ -29.5%
Long-Term Debt Long-term obligations
$9.04B
— 0.0%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
88
Returns
99
Financial Health
9
Cash Quality
58

Dividend History

Dividend / share · sourced from SEC filings
$2.03 Latest / share
+13.0% YoY
+20.3% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 56 quarters